Abstract
The Bedford, Massachusetts, start-up Verseau Therapeutics has launched with $50 million to develop immunotherapies that target a class of immune cells called macrophages. Existing checkpoint inhibitor therapies help activate T cells to attack some tumors, but the drugs don’t work for everyone. Verseau hopes it can treat more cancers by targeting proteins that can activate macrophages. Many of the firm’s lead programs are antibodies, but it also has licensed lipid nanoparticles from Bob Langer and Dan Anderson’s labs at the Massachusetts Institute of Technology to deliver silencing RNA therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
